Jiawei Zhang, Nanxuan Luo, Yijie Xiao, Zhangshun Luo, Lijie Lv, Jia Zheng, Jie Li, Xuan Li, Zhe-Yang Hu, Jian Min, Yahui Zhao*, Yi He*, Shenyou Nie* and Hai-Xin Yuan*,
{"title":"苯并二硝基[2,3-b]吡啶伪天然产物作为一类新型铁蛋白抑制剂的鉴定","authors":"Jiawei Zhang, Nanxuan Luo, Yijie Xiao, Zhangshun Luo, Lijie Lv, Jia Zheng, Jie Li, Xuan Li, Zhe-Yang Hu, Jian Min, Yahui Zhao*, Yi He*, Shenyou Nie* and Hai-Xin Yuan*, ","doi":"10.1021/acs.jmedchem.5c01942","DOIUrl":null,"url":null,"abstract":"<p >Ferroptosis is a form of regulated cell death mediated by iron-dependent phospholipid peroxidation. Pharmacological inhibition of ferroptosis has been considered a promising therapeutic approach for various diseases. In this study, by integrating pseudonatural concepts with our newly developed rhodium-catalyzed C–H activation/Lossen rearrangement/oxa-Michael addition methodology, we rapidly assembled diverse benzofuro[2,3-<i>b</i>]pyridine PNP derivatives and systematically evaluated their antiferroptotic activity. Among these compounds, <b>4k</b> exhibited significant activity in suppressing ferroptosis. We further elucidated that <b>4k</b> acts as a novel and specific inhibitor of ferritinophagy by targeting NCOA4 and disrupting its interaction with ferritin. Subsequent results demonstrated that <b>4k</b> effectively ameliorated ConA-induced acute liver injury. Collectively, our findings indicate that <b>4k</b>, featuring benzofuro[2,3-<i>b</i>]pyridine PNP scaffolds, acts as a selective inhibitor and could serve as a potential lead compound for further research. This work suggests that pharmacological targeting of the NCOA4-FTH1 interaction represents a promising intervention strategy for ferroptosis-related diseases.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 17","pages":"18703–18726"},"PeriodicalIF":6.8000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Identification of Benzofuro[2,3-b]pyridine Pseudonatural Product as a Novel Class of Ferritinophagy Inhibitors that Potently Suppress Ferroptosis\",\"authors\":\"Jiawei Zhang, Nanxuan Luo, Yijie Xiao, Zhangshun Luo, Lijie Lv, Jia Zheng, Jie Li, Xuan Li, Zhe-Yang Hu, Jian Min, Yahui Zhao*, Yi He*, Shenyou Nie* and Hai-Xin Yuan*, \",\"doi\":\"10.1021/acs.jmedchem.5c01942\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Ferroptosis is a form of regulated cell death mediated by iron-dependent phospholipid peroxidation. Pharmacological inhibition of ferroptosis has been considered a promising therapeutic approach for various diseases. In this study, by integrating pseudonatural concepts with our newly developed rhodium-catalyzed C–H activation/Lossen rearrangement/oxa-Michael addition methodology, we rapidly assembled diverse benzofuro[2,3-<i>b</i>]pyridine PNP derivatives and systematically evaluated their antiferroptotic activity. Among these compounds, <b>4k</b> exhibited significant activity in suppressing ferroptosis. We further elucidated that <b>4k</b> acts as a novel and specific inhibitor of ferritinophagy by targeting NCOA4 and disrupting its interaction with ferritin. Subsequent results demonstrated that <b>4k</b> effectively ameliorated ConA-induced acute liver injury. Collectively, our findings indicate that <b>4k</b>, featuring benzofuro[2,3-<i>b</i>]pyridine PNP scaffolds, acts as a selective inhibitor and could serve as a potential lead compound for further research. This work suggests that pharmacological targeting of the NCOA4-FTH1 interaction represents a promising intervention strategy for ferroptosis-related diseases.</p>\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"68 17\",\"pages\":\"18703–18726\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01942\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01942","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Identification of Benzofuro[2,3-b]pyridine Pseudonatural Product as a Novel Class of Ferritinophagy Inhibitors that Potently Suppress Ferroptosis
Ferroptosis is a form of regulated cell death mediated by iron-dependent phospholipid peroxidation. Pharmacological inhibition of ferroptosis has been considered a promising therapeutic approach for various diseases. In this study, by integrating pseudonatural concepts with our newly developed rhodium-catalyzed C–H activation/Lossen rearrangement/oxa-Michael addition methodology, we rapidly assembled diverse benzofuro[2,3-b]pyridine PNP derivatives and systematically evaluated their antiferroptotic activity. Among these compounds, 4k exhibited significant activity in suppressing ferroptosis. We further elucidated that 4k acts as a novel and specific inhibitor of ferritinophagy by targeting NCOA4 and disrupting its interaction with ferritin. Subsequent results demonstrated that 4k effectively ameliorated ConA-induced acute liver injury. Collectively, our findings indicate that 4k, featuring benzofuro[2,3-b]pyridine PNP scaffolds, acts as a selective inhibitor and could serve as a potential lead compound for further research. This work suggests that pharmacological targeting of the NCOA4-FTH1 interaction represents a promising intervention strategy for ferroptosis-related diseases.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.